Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Recruiting now · Phase 2/Phase 3

Conditions studied: Primary Membranous Nephropathy

In brief

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Key facts

Study ID
NCT07204275
Run by
Vertex Pharmaceuticals Incorporated
People needed
176
Starts
2025-09-30
Expected to finish
2028-12-29
Last updated by the study team
2026-08-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.